89Zr-immuno-PET is a promising noninvasive clinical tool that measures target engagement
of monoclonal antibodies (mAbs) to predict toxicity in normal tissues and efficacy in tumors …

Positron emission tomography (PET) with 89Zr-labeled monoclonal antibodies (mAbs) or
other targeted vehicles (eg., peptides, nanoparticles and cells), collectively called “89Zr …

The identification of molecular drivers of disease and the compelling rise of biotherapeutics
have impacted clinical care but have also come with challenges. Such therapeutics include …

The use of 89Zr-antibody PET imaging to measure antibody biodistribution and tissue
pharmacokinetics is well established, but current PET systems lack the sensitivity needed to …

Purpose In-vivo quantification of tumor uptake of 89-zirconium (89 Zr)-labelled monoclonal
antibodies (mAbs) with PET provides a potential tool in strategies to optimize tumor targeting …

Immuno-PET as a scouting procedure before radioimmunotherapy (RIT) aims at the
confirmation of tumor targeting and the accurate estimation of radiation dose delivery to both …

Purpose Positron emission tomography imaging of zirconium-89-labelled monoclonal
antibodies (89Zr-Immuno-PET) allows for visualisation and quantification of antibody uptake …

The development of noninvasive imaging techniques using monoclonal antibodies (mAbs)
is a quickly evolving field. Immuno-PET uses positron-emitting isotopes to track the …

Simple Summary The uptake on a 89Zr-immuno-PET scan is not just the result of the binding
of a radiolabeled antibody with its target (ie, target engagement) but also includes …

Selection of the right drug for the right patient is a promising approach to increase clinical
benefit of targeted therapy with monoclonal antibodies (mAbs). Assessment of in vivo …